Beate Hauptrock

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

Dietrich W. Beelen, Rudolf Trenschel, Matthias Stelljes et al. · The Lancet Haematology · 2019 · 147 citations · Full text

Increasing functional avidity of TCR-redirected T cells by removing defined <i>N</i> -glycosylation sites in the TCR constant domain

Jürgen Kuball, Beate Hauptrock, Victoria Malina et al. · The Journal of Experimental Medicine · 2009 · 144 citations · Full text

Coexpression of the T-cell receptor constant α domain triggers tumor reactivity of single-chain TCR-transduced human T cells

Ralf-Holger Voss, Simone Thomas, Christina Pfirschke et al. · Blood · 2010 · 51 citations · Full text

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

Matthias Stelljes, Jan Moritz Middeke, Gesine Bug et al. · The Lancet Haematology · 2024 · 44 citations · Full text

In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Matthias Stelljes, Jan Moritz Middeke, Gesine Bug et al. · Blood · 2022 · 41 citations

Hematological Malignancy, Transplantation, Marrow Transplantation +9